Logo image
Back
Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset
Journal article   Open access   Peer reviewed

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset

Katalin Vincze, Agnieszka Szwajda, Alexander Ploner, Robert Karlsson, Xiaoying Kang, Bowen Tang, Chenxi Qin, Cloé Domenighetti, Pierre-Emmanuel Sugier, Ashwin Ashok Kumar Sreelatha, …
NPJ Parkinson's Disease, Vol.12(1), 127
2026
DOI: https://doi.org/10.1038/s41531-026-01398-5
PMID: 42209523
pdf
Published1.15 MBDownloadView
Open Access CC BY V4.0

Abstract

To investigate whether antidiabetic drugs have a biological basis to be repurposed in PD prevention, we applied a drug target Mendelian randomization framework to assess associations between genetic variation in antidiabetic drug targets and PD risk or age at onset (AAO). Instrumental variables (IVs) were derived from GWAS summary statistics on fasting glucose (FG), glycated hemoglobin (HbA1c), and gene expression data from GTEx. Apart from SGLT2 inhibitors, all other antidiabetic drugs of interest could be instrumented through our methods. Positive and negative control analyses were carried out to validate 20 IVs in the FG arm and 23 IVs in the HbA1c arm. DPP-4 inhibitors failed the positive control. GWAS summary statistics for PD risk and AAO data were sourced from the IPDGC and COURAGE-PD consortia, resulting in 42 083 cases/457 090 controls for risk and 37 103 PD cases for AAO. MR analyses showed no significant associations across consortia or in meta-analysis. These findings do not support a causal role of genetic variation in antidiabetic drug targets in PD risk or AAO.

Details

Metrics

1 Record Views
Logo image